More prescription-strength Zantac recalled. It might have too much of a carcinogen
After a quiet December, recalls of ranitidine — brand name: Zantac — resumed Tuesday with Appco Pharma pulling all quantities and lots of 150mg and 300mg ranitidine hydrochloride capsules.
The problem, according to the company-written, FDA-posted recall notice, is NDMA-related, as has been the case with previous recalls. Recalled capsules might have more N-nitrosodimethylamine, classified as a probable human carcinogen, than FDA acceptable intake levels.
Recalled batch Nos. are 1906295UN, 1906296UN and 1906297UN for 150mg capsules in 60-count bottles with expiration date May 2021; 1905227UE and 1905228UE for 300mg capsules in 30-count bottles with expiration date April 2021; 1905225VN for 150mg capsules in 60-count bottles (expiration date April 2021); 1905226VD for 150mg capsules in 500-count bottles (expiration April 2021); and 1906298UD for 500-count bottles with expiration date May 2021.
Patients should stop taking the capsules, return them to the place of purchase if possible and discuss another form of treatment with a doctor or pharmacist.
Appco Pharma’s ranitidine was distributed by ANI Pharmaceuticals, whose logo is largest on the bottles. Anyone with questions about the recall can call Appco at 732-253-7735, Monday through Friday, 8 a.m. to 6 p.m., Eastern time; email pv@appcopharma.com; call ANI at 800-308-6755; or email PVSupport@safetycall.com.
This story was originally published January 8, 2020 at 10:55 AM with the headline "More prescription-strength Zantac recalled. It might have too much of a carcinogen."
